INVO Fertility (IVF) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jul, 2026Opening remarks and agenda
The meeting was called to order virtually at 12:00 P.M. ET on July 23, 2026, with key executives and board members present.
The agenda included voting on seven proposals, including board elections, auditor ratification, amendments to articles of incorporation, stock issuances, and incentive plan changes.
Board and executive committee updates
Steve Shum, CEO, chaired the meeting, with participation from the CFO, Corporate Secretary, legal counsel, and Inspector of Election.
Shareholder proposals
Proposals included electing five directors, ratifying the auditor, increasing authorized shares, approving warrant-related stock issuance, amending the stock incentive plan, authorizing future equity financing, and allowing adjournment for additional proxy solicitation.
Latest events from INVO Fertility
- Q2 2026 revenue rose 18% year-over-year, with net income of $0.9 million and improved liquidity.IVF
Q2 2026 - Up to 20 million shares may be sold to fund fertility clinic expansion, with significant dilution risk.IVFRegistration filing
- Shareholders will vote on key proposals to expand capital, amend governance, and align incentives.IVFProxy filing
- Q1 2026 revenue rose 23% to $2.0M, but ongoing losses and funding needs raise going concern risks.IVFQ1 2026
- Clinic network expansion and INVOcell innovation drive growth and improved financial outlook.IVFPlanet MicroCap Las Vegas 2026
- Clinic network and technology-driven growth boost revenue and operational scale.IVFCorporate presentation
- Shareholders are asked to approve director elections, major capital changes, and key governance proposals.IVFProxy filing
- Revenue up 5% and net loss narrowed as four-clinic network and balance sheet strengthened.IVFQ4 2025
- Revenue and EBITDA improved sharply as acquisitions and technology drive clinic growth.IVFCorporate presentation